New York, February 16, 2026, 15:16 EST — The session has ended.
Shares of Thermo Fisher Scientific Inc slipped almost 1% Friday, capping off a four-day losing streak ahead of Monday’s market holiday. The stock settled at $504.82.
With cash trading on hold, focus turns to Tuesday’s open. Investors are sorting out if this pullback is just regular risk-paring or the start of a deeper repricing of the company’s 2026 expectations and its aggressive acquisition streak.
Thermo Fisher shares have dropped roughly 6.5% since the close on Feb. 10, logging four consecutive declines, company stock records show.
Life-sciences tools stocks took divergent paths Friday. Danaher dropped close to 1.2%. Agilent, on the other hand, managed a gain of around 0.7%.
Attention has turned for now to how Thermo Fisher will bankroll the Clario acquisition. On Feb. 9, the company announced it had priced $3.8 billion in dollar-denominated senior notes, breaking the issuance into four different maturities. Thermo Fisher plans to put those net proceeds toward the cash portion of the Clario deal.
Thermo Fisher disclosed in a Feb. 12 SEC filing that it issued the notes, aiming to raise roughly $3.76 billion in net proceeds after factoring in underwriting discounts and other expenses. The same filing noted that the Clario acquisition still needs to clear standard closing hurdles, regulatory approvals among them.
Back in October, Thermo Fisher struck a deal to acquire Clario—a privately held clinical services firm—for as much as $9.4 billion, aiming to bolster its position in clinical trial research and data services. Analyst Puneet Souda of Leerink Partners described this as a shift toward a “more steadily growing and attractive area” versus early-stage research, according to Reuters. Reuters
Thermo Fisher’s business environment has been a factor, too. Back on Jan. 29, the company projected 2026 adjusted earnings—profits minus certain items—would land between $24.22 and $24.80 per share, with revenue guidance set at $46.3 billion to $47.2 billion. The company also pointed to ongoing pressure from U.S. academic research funding. CEO Marc Casper told analysts he expects “similar conditions to last year” for the firm’s academic and government segments. Reuters
Casper flagged another boost: pharmaceutical companies moving manufacturing back to the U.S. “There’s a very big focus on reshoring more production and activity to the U.S.,” he said during the J.P. Morgan Healthcare Conference, and described it as a positive force through 2027 and 2028. Reuters
This stock tends to move sharply on sentiment shifts. If the Clario timeline slips, or if research and biotech budgets get cut further, the notion that demand evens out later this year could get challenged.
Macro might have to pick up the slack for now. Investors are eyeing the Fed’s Jan. 27-28 meeting minutes, due out Wednesday, Feb. 18 at 2 p.m. ET. Then on Friday, Feb. 20 at 8:30 a.m. EST, the Commerce Department drops its personal income and outlays data, including the PCE price index—the inflation marker the Fed favors.
